Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test may spot hidden pancreatic cancer earlier after surgery

NCT ID NCT07597252

Knowledge-focused Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining cancer earlier than current methods, which could help design future treatment studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with histologically confirmed pancreatic ductal adenocarcinoma who underwent R0 or R1 (margin \<1 mm) curative resection at Linkou Chang Gung Memorial Hospital, recruited consecutively from the oncology and general surgical outpatient clinics during their post-operative follow-up. No public advertising or open recruitment used.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 20 years or older * Histologically confirmed pancreatic ductal adenocarcinoma (PDAC), including its histological subtypes * Has undergone curative-intent resection (R0 or R1, defined as margin \<1 mm), via pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy * Post-operative pathologic stage at least pT1, with N0 or N1 or higher * Computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks before enrollment confirming no evidence of residual tumor and no distant metastasis * Intent to receive adjuvant chemotherapy * Sufficient surgical FFPE tumor tissue available for genomic sequencing * Able to understand and provide signed informed consent * Patients with or without prior neoadjuvant chemotherapy are both eligible Exclusion Criteria: * Post-operative pathologic stage IV (distant metastasis), or R2 resection * Concurrent active primary malignancy (except cured non-melanoma skin cancer or carcinoma in situ within the past 5 years) * Severe post-operative complications precluding initiation of adjuvant chemotherapy within 12 weeks * Receipt of post-operative radiation therapy * Known hematologic disease or myeloproliferative disorder that may significantly affect ctDNA assay accuracy * Pregnant or breastfeeding women * Unable to comply with the protocol-specified blood draw schedule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NGS monitor MRD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NGS monitor MRD Pancreatic ductal adenocarcinoma (PDAC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.